John Sculley - Kaleido Biosciences Director
| KLDODelisted Stock | USD 0.01 0.00 0.00% |
Director
Mr. John Sculley is Director of the Company. Mr. Sculley is Vice Chairman for Celularity, Inc., a placenta cord blood stem cell company, and Chairman of the Board of Directors and Chief Marketing Officer for RxAdvance Corporationrationration, a modern Pharmacy Benefit Manager platform company. He is also the Cofounder and Vice Chairman of Zeta Global, a personalized marketing platform. Mr. Sculley was previously Chief Executive Officer of PepsiCola Co. and the Chief Executive Officer of Apple Inc. He was a founding Board member of MetroPCS Communications, Inc. and Rally Health, Inc since 2018.
| Tenure | 6 years |
| Professional Marks | MBA |
| Phone | 617 674 9000 |
| Web | https://kaleido.com |
Kaleido Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.9993) % which means that it has lost $0.9993 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.8057) %, meaning that it created substantial loss on money invested by shareholders. Kaleido Biosciences' management efficiency ratios could be used to measure how well Kaleido Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 5.55 M in liabilities with Debt to Equity (D/E) ratio of 2.05, implying the company greatly relies on financing operations through barrowing. Kaleido Biosciences has a current ratio of 1.39, which is within standard range for the sector. Debt can assist Kaleido Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Kaleido Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kaleido Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kaleido to invest in growth at high rates of return. When we think about Kaleido Biosciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Matthew Young | CytomX Therapeutics | 49 | |
| James Meyers | CytomX Therapeutics | 54 | |
| Anthony Altig | Assembly Biosciences | 61 | |
| Anne Urlwin | Instil Bio | N/A | |
| Gaggar | Instil Bio | 85 | |
| Charles Fuchs | CytomX Therapeutics | 57 | |
| Myron Holubiak | Assembly Biosciences | 70 | |
| George Rohlinger | Instil Bio | N/A | |
| Ramana Rao | Instil Bio | N/A | |
| Elaine Jones | CytomX Therapeutics | 60 | |
| Donald Oborowsky | Ceapro Inc | N/A | |
| Ulrich Kosciessa | Ceapro Inc | N/A | |
| Geoffrey Swier | Instil Bio | N/A | |
| Alan Lewis | Assembly Biosciences | 71 | |
| Michael Maslowski | Instil Bio | N/A | |
| Richard DiMarchi | Assembly Biosciences | 64 | |
| Veena Hingarh | Instil Bio | N/A | |
| Tridibesh Mukherjee | Instil Bio | 74 | |
| Neil Exter | CytomX Therapeutics | 57 | |
| Frederick Gluck | CytomX Therapeutics | 82 | |
| John Scarlett | CytomX Therapeutics | 67 | |
Management Performance
| Return On Equity | -5.81 | ||||
| Return On Asset | -1.0 |
Kaleido Biosciences Leadership Team
Elected by the shareholders, the Kaleido Biosciences' board of directors comprises two types of representatives: Kaleido Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kaleido. The board's role is to monitor Kaleido Biosciences' management team and ensure that shareholders' interests are well served. Kaleido Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kaleido Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Geoffrey Maltzahn, President Co-Founder | ||
| Jeremy Buzzard, Senior Vice President - Corporate Development | ||
| Johannes Vlieg, Chief Scientific Officer | ||
| Grady Burnett, Director | ||
| Mark Wingertzahn, VP Devel | ||
| Bonnie Bassler, Director | ||
| Jeffery Moore, Senior Vice President - Finance & Administration | ||
| Clare Fisher, Chief Business Officer | ||
| LLM JD, Chief Advisor | ||
| Jerald Korn, General Counsel, Corporate Secretary | ||
| Mike Bonney, Chairman of the Board, CEO | ||
| John Sculley, Director | ||
| Ruth ThieroffEkerdt, Chief Medical Officer | ||
| Theo MelasKyriazi, Independent Director | ||
| Kimberly Hocknell, VP Operations |
Kaleido Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Kaleido Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.81 | ||||
| Return On Asset | -1.0 | ||||
| Operating Margin | (79.28) % | ||||
| Current Valuation | (16.73 M) | ||||
| Shares Outstanding | 42.62 M | ||||
| Shares Owned By Insiders | 0.73 % | ||||
| Shares Owned By Institutions | 0.36 % | ||||
| Number Of Shares Shorted | 2.34 M | ||||
| Price To Earning | (1.45) X | ||||
| Price To Book | 0 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kaleido Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kaleido Biosciences' short interest history, or implied volatility extrapolated from Kaleido Biosciences options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Kaleido Pink Sheet
If you are still planning to invest in Kaleido Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kaleido Biosciences' history and understand the potential risks before investing.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges |